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The treatment of most patients with head and neck cancer includes ionizing radiation (IR). Salivary glands in the IR field suffer significant and
irreversible damage, leading to considerable morbidity. Previously, we reported that adenoviral (Ad)-mediated transfer of the human aquaporin-1
(hAQP1) cDNA to rat [C. Delporte, B.C. O’Connell, X. He, H.E. Lancaster, A.C. O’Connell, P. Agre, B.J. Baum, Increased fluid secretion after
adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc. Natl. Acad. Sci. U S A. 94 (1997) 3268-3273] and
miniature pig [Z. Shan, J. Li, C. Zheng, X. Liu, Z. Fan, C. Zhang, C.M. Goldsmith, R.B. Wellner, B.J Baum, S. Wang. Increased fluid secretion
after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. Mol. Ther. 11 (2005) 444-451]
salivary glands ¨16 weeks following IR resulted in a dose-dependent increase in salivary flow to 80% control levels on day 3. A control Ad
vector was without any significant effect on salivary flow. Additionally, after administration of Ad vectors to salivary glands, no significant lasting
effects were observed in multiple measured clinical chemistry and hematology values. Taken together, the findings show that localized delivery of
AdhAQP1 to IR-damaged salivary glands is useful in transiently increasing salivary secretion in both small and large animal models, without
significant general adverse events. Based on these results, we are developing a clinical trial to test if the hAQP1 cDNA transfer strategy will be
clinically effective in restoring salivary flow in patients with IR-induced parotid hypofunction.
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abbreviations are used: ITR, inverted terminal repeat; PCMV, cytomegalovirus
immediate early promoter/enhancer; hAQP1, human aquaporin-1 cDNA; SV40
polyA, Simian Virus 40 polyadenylation signal; DE1, deletion of adenoviral E1
sequences; E2, adenoviral E2 genes; E3, adenoviral E3 genes; E4, adenovira
E4 genes.1. Introduction
Each year ¨30,000–40,000 patients develop head and neck
cancer in the USA, with ¨400,000 cases worldwide [1,2]. The
treatment for the vast majority of such patients in industrialized
countries includes ionizing radiation (IR) [3,4]. A significant
side effect of IR treatment is damage to normal tissues in the IR
field [5], which can lead to reduced quality of life and
significant disability in head and neck cancer patients [4,6]. In
particular, salivary glands in the IR field can be severely
damaged, resulting in dramatic reductions in saliva production
and considerable morbidity [3,7–11]. Although the exact
mechanism for IR-induced salivary gland damage remains
somewhat enigmatic [12], fluid-secreting acinar cells are lost,
and relatively water-impermeable duct cells survive [7–9].
Saliva is critical for the physiology and protection of upper
gastrointestinal (GI) tract tissues, providing critical antimicro-
bial, lubricatory and reparative functions [13]. Following IR
treatment, patients experience oral infections, such as candidi-
asis and rampant dental caries, mucositis, dysphagia and frank
discomfort leading to a marked decline in quality of life
[3,4,10]. There is no adequate conventional therapy available
to correct IR-induced salivary hypofunction and most treatment
options are essentially palliative in nature [8,9,14]. It was the
absence of a conventional therapy for IR-induced salivary
hypofunction that initially prompted our efforts to utilize gene
transfer [15,16].
Salivary glands are an unusual but appealing target site for
in vivo gene transfer [17–19]. The duct orifice of each major
salivary gland (parotid, submandibular–sublingual) is readily
visible in the mouth. This orifice is directly contiguous with
virtually every epithelial cell in the gland via the duct lumen
[17,19]. Additionally, salivary glands are a site of considerable
protein synthesis, albeit for exocrine purposes normally.
Transgene expression in these glands after administration of a
first-generation recombinant serotype 5 adenoviral (rAd5)
vector generally follows the distribution of av, h3/5 integrins
along acinar and duct cell luminal membranes, and almost all
cell types can be transduced [20]. Many different types of
transgene products have been expressed in various cell lines,
including a salivary epithelial cell line; all of which were
correctly targeted to their appropriate subcellular location [21].
This suggests that appropriate targeting likely will occur in
native tissues. Our aggregate studies clearly show that first
generation rAd5 vectors can readily infect and direct transgene
expression in mammalian salivary glands [17,19].
To address IR-induced salivary hypofunction, we hypothe-
sized that the critical element needed to provide upper GI tract
protection and lubrication is water, reasoning that adequate
water secretion by surviving epithelial cells within the gland
would dissolve the protective exocrine proteins produced byundamaged duct cells and remaining acinar cells, and deliver
them to the upper GI tract [22]. Although the physiology of
normal salivary duct cells is not well understood, based on
available evidence, we postulated that after IR duct cells could
generate an osmotic gradient (lumen> interstitium) allowing
fluid secretion if a facilitated water permeability pathway was
introduced [22]. We therefore hypothesized that increasing the
water permeability of surviving salivary duct cells via transfer
of the human aquaporin-1 (hAQP1) cDNA could accomplish
this [22–24]. To achieve gene transfer, we constructed a rAd5
vector encoding hAQP1. This brief review describes our efforts
to move AdhAQP1 (Fig. 1) from the laboratory bench to
clinical trials with patients suffering from IR-induced parotid
gland hypofunction.
2. Vector construction and in vitro efficacy studies
To construct AdhAQP1 (Fig. 1, [22]), the hAQP1 cDNA
[23] was cloned directly into the Ad5 shuttle vector pACCMV-
pLpA (a gift from Dr. C. Newgard, University of Texas,
Southwestern Medical Center [25]). This plasmid contains part
of the Ad5 genome (0–1.2 and 9.2–17 Am) with the human
cytomegalovirus immediate early promoter/enhancer substitut-
ed between map units 1.3 and 9.1 (Ad5 E1 region; Fig. 1). PCR
amplification of the hAQP1 cDNA (¨3 kb) was performed
using specific primers containing KpnI and BamHI restriction
sites for cloning [22]. The resultant plasmid, termed pCMV-
hAQP1, was co-transfected with the Ad5 plasmid pJM17 into
293 cells as described [25], to yield AdhAQP1. This vector,
with subsequent plaque-purifications, has been used in all
studies described herein, including in vitro cell culture and in
vivo animal model experiments. This vector will also be
produced at a clinical grade for the planned clinical studies
described below.
Initial in vitro characterization of AdhAQP1 used three
epithelial cell lines that do not endogenously express hAQP1;l
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AdhAQP1, Western blot analyses of crude membranes
prepared from all cell lines were positive for the presence of
hAQP1. Thereafter, we evaluated the cellular distribution and
function of the transgenic hAQP1 by infection of a polarized
monolayer of MDCK cells with AdhAQP1. The transgenic
hAQP1 could be detected uniformly distributed around the
basolateral and apical cell membranes of MDCK cells by
confocal microscopy and mediated a 4-fold increase in
osmotically-obliged net fluid secretion across both MDCK
and SMIE monolayers (e.g., see Fig. 2; [21,22]).
In order to study transgenic hAQP1 physiological function,
we used the SMIE cell line, which provides an in vitro model
of a polarized salivary epithelium, and has been characterized
in detail [21]. We extensively tested the relationship between
AdhAQP1 vector- mediated expression of hAQP1 and fluid
movement across this model epithelium [24]. To do this, we
infected polarized SMIE cell monolayers grown in Transwell-
Col (polycarbonate filters coated with collagen) chambers with
AdhAQP1 at different multiplicities of infection (MOIs;
defined for in vitro studies as plaque-forming units [pfu]/cell)
and subsequently examined fluid movement in response to an
osmotic gradient (440 to 340 mosm; apical to basal).
Osmotically obliged fluid movement occurred rapidly in
response to imposition of the gradient 24-h after infection
with the vector at a MOI of 5. Fluid movement was linear for
15–30 min [24], with an initial rate of ¨2–3 AL/min, which
was much greater than that of uninfected cells (¨0.1 AL/min),
and also was proportional to the osmotic gradient applied [24].
Furthermore, both the expression of hAQP1 in SMIE cell
membranes and fluid movement were AdhAQP1 dose-depen-
dent (0–10 MOI). A MOI of as little as 0.1 led to detectable
expression by Western blotting, which increased ¨80–100Fig. 2. Effect of AdhAQP1 infection on net fluid movement across SMIE cells.
Data shown are the meanTS.E.M. of experiments reported in He et al. [21].
SMIE cell monolayers were either infected at a MOI=5 with AdhAQP1 or
AdCMVhGH (encoding human growth hormone), and 24 h later transepithelial
fluid movement was measured for 60 min.fold at the highest MOIs (5–10) [24]. Importantly, at relatively
low vector doses (and hAQP1 expression levels) fluid
movement was disproportionately high, being linear between
0–1.0 MOI, while thereafter it began to plateau and changed
little (<5%) between a MOI of 5 and 10. An implication of
these latter results is that it could be unnecessary to achieve
high hAQP1 protein expression levels in transduced salivary
epithelial cells in vivo for correction of IR-induced salivary
gland hypofunction.
3. In vivo efficacy studies
Initially, we studied rats whose submandibular glands were
subjected to a single IR dose of 21 Gy [22]. Four months
following IR rats exhibited a dramatic reduction in salivary
flow and were administered either a single dose (5109 pfu/
gland; ¨100 vector particles:pfu; in 200 AL, i.e., 2.5107 pfu/
AL) of AdhAQP1, or a control virus (Addl312; no encoded
transgene), via retrograde submandibular duct instillation.
Three days later, stimulated saliva was collected from all rats
following a pilocarpine (parasympathomimetic) stimulus. The
control virus had no beneficial effect on salivary flow (Table 1)
and the control virus-treated irradiated rats exhibited marked
salivary hypofunction (¨35% of the salivary flow of sham-
irradiated rats; not shown). Conversely, rats given AdhAQP1
(TIR) displayed salivary flow rates approaching those of sham-
irradiated animals treated with a control virus [22].
We next examined the utility of AdhAQP1 for repairing IR
damage in non-human primates [26]. One parotid gland of five
8–10 kg rhesus monkeys was irradiated with a single dose of 10
Gy. This dose significantly reduced salivary flow in all monkeys
(¨50–90%; [26]). AdhAQP1 (either 2109 or 1108 pfu/gland
in 0.5 mL) was administered intraductally at 19 weeks post-IR
and salivary secretion examined 3, 7 and 14 days later. Note that
the choice of a 19-week time point between IR and vector
delivery, versus the similar ¨16-week intervals used in the rat
and minipig (below) studies, was made for experimental
convenience. The results, however, were inconsistent, and only
2 of the 4 AdhAQP1-treated monkeys displayed any increase of
salivary flow rates compared to the single animal administered
an irrelevant virus [26]. Possible reasons for the disparity from
the rat studies include an inadequate perfusion of the virus into
the primate glands, differences between these animal models in
the distribution of viral receptor on the luminal surfaces of gland
cells, as well as physiological or pathophysiological differences
in the target cells. Subsequently, we repeated studies in irradiated
rats and generally confirmed the efficacy of the AdhAQP1 vector
in restoring salivary fluid output [22,27]. Thus, following the
non-human primate study, it was not clear whether the strategy
of hAQP1 cDNA transfer would be useful for correction of
existing IR damage in salivary glands of animals larger than rats.
In order to test further whether AdhAQP1 would be
effective at improving salivary secretion in irradiated salivary
glands of a large animal, we chose to evaluate a different
model, the miniature pig (minipig; ¨35 kg), which is more
readily, and affordably, studied [28,29]. Sixteen weeks follow-
ing IR (20 Gy) salivation from the targeted parotid gland was
Table 1
Effect of AdhAQP1 on salivary secretion in irradiated animalsa






a This table is a summary of data previously reported in Delporte et al. [22]
and Shan et al. [30]. For the rat experiments, animals received 21 Gy, while the
minipigs received 20 Gy, each in a single dose. The data shown are the average
percent of control salivary flow results seen three days following vector
delivery. 100% would be equivalent to control (i.e., normal) salivary flow.
b Control data in the rat experiments were derived from animals that were not
irradiated but infected with a control vector. Control data in the minipig
experiments were derived from the pre-irradiation salivary flow rates in the
same animals.
c Addl312 is a rAd5 vector without any encoded transgene.
d AdCMVLuc is a rAd5 vector encoding firefly luciferase.
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in a dose-dependent increase in parotid salivary flow to ¨80%
pre-IR levels on day 3 (Table 1; [30]). A control rAd5 vector
encoding firefly luciferase was without significant effect on
salivary flow. The effective dose of AdhAQP1 used was 109
pfu /gland, equivalent to 2.5105 pfu/AL infusate, a dose
leading to a comparable (scaled) transgene expression in
murine and minipig salivary glands [28]. It is noteworthy that
this effective dose was only 20% of the total dose shown to be
effective in our earlier irradiated rat studies [22].
The only minipig parotid cell types that were found to express
the transgenic hAQP1 in immunohistochemical studies were
intralobular and interlobular ductal cells. No evidence was found
for AdhAQP1-mediated transgenic hAQP1 expression in
surviving parotid acinar cells. Our previously reported studies
in non-irradiated minipigs [28] showed that the volume in which
we infused administered vector (4000 AL) was sufficient to
permit reasonable vector contact with acinar cells and indeed
those studies clearly demonstrated that rAd5 vectors could
transduce minipig parotid acinar cells [28]. In irradiated rat
submandibular glands [22], AdhAQP1 administration can
effectively result in transduced acinar cells. Since the hAQP1
transgene was expressed only in parotid ductal cells, the
implication of our minipig study is that the increased salivary
secretion observed was likely due to enhanced water perme-
ability in the normally water-impermeable duct cells [30].
The specific mechanism (osmotic gradient) by which fluid
secretion occurred from the hAQP1-expressing duct cells has
not been established, however. We hypothesized, based on the
irradiated rat study [22], that AdhAQP1 likely elicited fluid
secretion from ductal cells via a KHCO3-generated gradient
(lumen>interstitium). Our minipig study suggests this mecha-
nism is still possible, but we have yet to account for all of the
required osmolytes [30]. Although the osmotic mechanism is
not clear, our aggregate findings in minipigs demonstrated that
localized delivery of AdhAQP1 to IR-damaged parotid glands
is effective in increasing salivary secretion in a large animal
model, without any significant general adverse events (see
below), and lend support for the notion that hAQP1 cDNAtransfer may be clinically useful for patients with IR-induced
salivary hypofunction.
4. Pre-clinical toxicology studies
To advance this potential treatment into clinical trials, in
addition to efficacy studies, it is necessary to conduct detailed
toxicological and bio-distribution studies to ensure patient
safety. GLP is an acronym for Good Laboratory Practice, a
defined level of conduct for non-clinical studies established by
the US Food and Drug Administration (FDA; [31]). Accord-
ingly, soon after we initially demonstrated that AdhAQP1 led to
increased salivary flow in irradiated rats [22], we began to
conduct both non-GLP and GLP-level studies with AdhAQP1
and related first generation rAd5 vectors [32–34]. Herein, we
use the term non-GLP to identify high quality laboratory
research studies. Good Manufacturing Practice (GMP) is the
level of conduct required for materials intended for use in human
(clinical) studies [35].
4.1. Non-GLP studies with AdhAQP1
All of the non-GLP level safety studies that we have
conducted so far with any rAd5 vector have indicated the same
conclusion regardless of species tested; evidence of local, dose-
dependent vector related inflammatory changes in the target
gland, but no evidence for significant systemic manifestations
of vector delivery to salivary glands [26,28,32]. A detailed
description of rAd5 vector-induced inflammatory changes in
salivary glands was previously reported [36]. Initially, we
conducted a study examining the safety of AdhAQP1
administration to rat submandibular glands [32]. In that study,
we administered either buffer, a control rAd5 vector not
encoding a transgene (Addl12) or AdhAQP1, at a high vector
dose, 5109 pfu/gland (i.e., the dose used in rat efficacy
studies [22]), to male Wistar rats (250–300 g). Animals were
followed for up to 9 days, and detailed serum chemistries and a
complete gross and limited (liver, spleen, pancreas, lung,
kidney, stomach) microscopic necropsy were performed after
sacrifice. On days 1 and 9, most clinical chemistry (blood urea
nitrogen, creatinine, total protein, albumin, total bilirubin,
cholesterol, calcium, sodium, globulin) and hematology (he-
moglobin, hematocrit, red blood cells, mean corpuscular
volume, mean corpuscular hemoglobin concentration) values
were not different between buffer- and AdhAQP1-treated rats.
However, on days 1 and 9 when compared to the buffer-treated
rats, systemic evidence of inflammation (i.e., increased levels
of lactate dehydrogenase and white blood cells) was seen, after
AdhAQP1 delivery to salivary glands at this high vector dose.
The non-GLP level study performed in non-human primates,
while equivocal with respect to AdhAQP1 efficacy, as described
above, indicated that administration to parotid glands of either
2109 or 1108 pfu/gland AdhAQP1 was without untoward
local (salivary) or systemic (serum chemistry, hematology)
effects [26]. Similarly, our non-GLP level studies with rAd5
vectors in minipigs (described above; [28,30]) showed that all
animals remained healthy and exhibited no clinically significant
Table 2
Summarized results of completed GLP toxicological studies of rAd5 vector
delivery to rat submandibular glandsa
Vector AdCMVH3 AdCMVhGH
Reference [33] [34]
Dosesb 109 pfu 1011 particles
Length of study 15 days 28 days
Survivalc 100% 100%
Clinical signsd No significant No significant
Food consumption No change No change
Weight gain No change No change
Histopathologye Targeted SMG Targeted SMG
Clinical chemistryf No change Globulin increased
Hematologyg NRh No change
RCAi None detected None detected
a Results presented are from comparisons with controls within the same
study. Similar results were found for both male and female rats.
b For AdCMVH3 the following doses were administered: 0, 106, 3107 or
109 pfu (¨100 particles/pfu). For AdCMVhGH the following doses were
administered: 0, 2.4106, 6109 or 1.51011 viral particles. Zero indicates
diluent buffer was administered.
c Percentage of animals surviving until day of scheduled sacrifice.
d No toxicologically significant clinical signs were noted in rats of either
gender.
e The only consistent histopathological change observed that was considered
vector-related was a vector dose-related inflammation in the targeted
submandibular gland (SMG).
f Serum samples were analyzed for the following components: alanine
aminotransferase, alkaline phosphatase, lactate dehydrogenase, sorbitol dehy-
drogenase, albumin, amylase, creatine kinase, globulin, total protein, blood
urea nitrogen, creatinine, glucose, total bile acids, chloride and sodium.
g The hematology parameters measured included red blood cell (RBC) count,
RBC morphologic assessment, hematocrit, hemoglobin, mean corpuscular
volume, packed cell volume, mean corpuscular hemoglobin, mean corpuscular
hemoglobin concentration, white blood cell (WBC) count, WBC differential,
reticulocyte count, platelet count and morphologic assessment.
h NR, not reported due to excessive hemolysis.
i Replication competent adenovirus.
1075B.J. Baum et al. / Biochimica et Biophysica Acta 1758 (2006) 1071–1077adverse reaction, locally or generally, after administration to
their parotid glands. As in rat studies, minipig parotid gland
tissue samples revealed the presence of a dose-dependent
inflammatory response [28]. While there were several transient
alterations in clinical laboratory parameters after rAd5 vector
delivery to minipig parotid glands, we found no significant
differences between the values measured before rAd5 vector
delivery and those after 14 days; essentially all clinical chemistry
and hematology parameters were within normal limits [28]. For
these studies, the analyses performed were extensive and
included serum calcium, potassium, sodium, chloride, glucose,
total protein, albumin, globulin, aspartate aminotransferase,
alanine aminotransferase, lactate dehydrogenase, blood urea
nitrogen, alkaline phosphatase, and creatinine. Hematology
included the number of white blood cells, red blood cells and
concentration of hemoglobin present. All minipigs could tolerate
a rAd5 dose of 2109 pfu (i.e., vector administered to both
glands) without clinically untoward effects.
4.2. GLP studies with rAd5 vectors
Two GLP-grade toxicology and biodistribution studies have
thus far been completed using rAd5 vectors and previously
reported (Table 2) [33,34]. In the first study, groups of fifteen
male and fifteen female Wistar rats were administered, via the
right submandibular duct, a single dose, either 106, 3107 or 109
pfu (¨100:1 particle: pfu), of a rAd5 vector, AdCMVH3,
identical to AdhAQP1, except for the encoded transgene
(histatin 3; H3). An additional group of fifteen males and fifteen
females were administered virus dilution buffer. Animals were
observed for up to 15 days for clinical signs of toxicity, and body
weights and food consumption were measured. An extensive
and specialized PCR necropsy was performed for scheduled
sacrifices [33] and collected tissues were either snap frozen in
liquid nitrogen for PCR analysis or fixed in 10% formalin for
histopathological evaluation.
All animals survived to their scheduled sacrifice and
showed no unusual clinical signs or effects on body weight
or food consumption (Table 2). Potential rAd5 vector-related
changes were observed during gross and microscopic evalua-
tion of the submandibular/sublingual salivary glands from male
and female rats from the high dose group at all time points and
were similar to those reported by us earlier [36]. The ‘‘no
observed effect level’’ was determined to be 106 pfu for both
male and female animals. All other lesions observed micro-
scopically were considered to be incidental findings. Addi-
tionally, we found little change in the extensive set of serum
chemistry and hematology parameters that we measured
between the various animal groups studied. As in our non-
GLP level studies, we found in this GLP level study that rAd5
vector was without significant general adverse effect even at
absolute doses those planned for future clinical use.
Using a PCR assay (able to detect 100 viral particles/0.5 Ag
extracted DNA), various organs, as well as oral tissues, were
tested for the presence of AdCMVH3. At the 15-day time
point, no virus was detectable in the tissues of any of the
control animals. Virus was also undetectable in the gonads ofanimals in all groups at day 15. Occasional positive results
were seen in organs other than salivary glands or oral tissues,
most commonly at the highest vector dose (see [33]). The
saliva of four animals (two male, two female; treated with 109
pfu AdCMVH3 and exhibiting strongly positive PCR results
with DNA from their targeted submandibular gland indicating
significant vector levels) was tested for the presence of
replication competent adenovirus (RCA). RCA generation
following salivary gland administration of recombinant vector
would be a significant concern because of the possibility for
shedding of virus in a body fluid with considerable infectious
potential. All four saliva samples were negative for RCA [33].
Recently, we reported toxicological and biodistribution
findings in a GLP study of a different rAd5 vector encoding
growth hormone (AdCMVhGH), administered to a single rat
submandibular gland in the presence of the anti-malarial/anti-
rheumatic drug hydroxychloroquine [34]. The AdCMVhGH
vector was associated with very limited toxicities, similar to
what was found in the AdCMVH3 study described above (see
Table 2). Thus far, both our non-GLP and GLP level studies
show that first generation rAd5 vectors result in no significant
general adverse effects after administration to mammalian
salivary glands. At present, we have almost finished the in-life
Table 3
Proposed AdhAQP1 clinical dose escalation scheme







For dosage comparison, in 1999 a rAd5 study at the University of Pennsylvania
resulted in the death of a young man [42]. The fatal (highest) dose delivered
was 3.81013 rAd5 particles, and the starting dose for that study was
1.861011 particles [42], with all doses administered intravascularly. The
maximum dose in the proposed study will be <0.3% that of the fatal dose in the
University of Pennsylvania study. The starting dose, 1.4108 particles/gland,
corresponds to a MOI (defined here as the viral plaque forming [infectious]
units/AL infusate) of ¨9.3103 (assuming a 15:1 particle: pfu ratio and an
infusion volume of 1 mL, while the maximum dose proposed (11011 particles/
gland) corresponds to a MOI of ¨6.7106 pfu/AL infusate. We previously
reported that there is comparable (scaled) transgene expression in murine
submandibular glands and minipig parotid glands with a MOI of ¨2.5105
pfu/AL [28]. This is also the same MOI that led to a restoration of parotid
salivary flow in irradiated minipigs [30] (see Table 1).
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to a single rat submandibular gland.
5. Rationale for gene therapy with Ad vectors for
IR-induced parotid hypofunction
The use of a rAd5 vector for initial hAQP1 gene transfer
studies in adults with IR-induced parotid gland hypofunction
is based upon several considerations. First, rAd5 vectors are
extremely efficient at transferring genes to many non- or
slowly dividing epithelial cells, like salivary glands [17].
Second, having a vector that leads to robust expression is
advantageous from a safety perspective because less of the
vector is needed to generate therapeutic transgenic protein
levels. Third, the rAd5 vector will be administered locally into
the well-encapsulated parotid gland thus reducing the risk of
systemic exposure. Finally, in the event the AdhAQP1
strategy is not useful in human parotid glands, vector activity
will be short-lived. However, if the strategy is useful, choice
of a rAd5 vector initially does not preclude subsequent use of
a vector with persistent expression for stable hAQP1 gene
transfer, e.g., a serotype 2 adeno-associated viral vector
[17,19,37].
5.1. Specific aim of clinical trial
The primary purpose of the proposed clinical protocol is to
test the safety of AdhAQP1 with some measures of efficacy
(i.e., it is a Phase I/II, dose escalation study) in patients with
established IR-induced parotid gland hypofunction. The
principal outcome measure for biological efficacy will be
parotid gland salivary output. The proposed AdhAQP1 doses
to be studied will increase from 1.4108 particles/gland
(estimated particle: pfu ratio of ¨15:1) to a maximum of
11011 particles/gland (Table 3). This maximal vector dose has
been shown to be without significant untoward effects
clinically in other target organs [38,39].
For each patient, only one gland will be infused with vector
in ¨1.0 mL infusion buffer, based on optimal gland infusion
volumes obtained from pre-entry sialograms. The study
population will include 15 individuals with IR-induced parotid
salivary hypofunction, defined as having an absence of
unstimulated (resting) parotid salivary flow and a stimulated
parotid salivary flow in the vector targeted gland >0 and <0.2
mL/min/gland. Enrolled patients will be individuals aged 18–
65 years old, who are able to provide informed consent and
who have received IR for head and neck cancer at least 5 years
previously, and have no evidence of recurrent tumor. The
choice of at least a 5-year interval between IR and AdhAQP1
delivery for the clinical study was made because patients who
are tumor free for 5 years after initial treatment have an
excellent prognosis for long-term survival [40]. Patients will
receive AdhAQP1 at the start of the study and be evaluated
thereafter on days 1 (at multiple times), 2, 3, 7, 14, 28, 42, 90,
120, 150, 180 and 360, and annually thereafter for 15 years, to
assess salivary flow as well as numerous routine general and
gene therapy-related safety-related parameters.A separate but important issue related to safety is
consideration of the possible risks, versus the potential benefits
of increased salivary secretion, to a patient as a result of
hAQP1 cDNA transfer. Based on the pre-clinical animal model
studies described above, there appears to be little to no risk of
hAQP1 cDNA gene transfer per se. For example, we found
that rAd5 vectors identical to AdhAQP1, except for the
encoded transgene (i.e., encoding instead of hAQP1 either
H3, hGH or luciferase), all showed similar safety profiles, i.e.,
the transgene encoded provided no additional effect [e.g.,
30,33,34]. Furthermore, although epithelial cells of salivary
duct do not normally express hAQP1, it is widely distributed in
a spectrum of different tissues. In several tissues, it is extremely
abundant, e.g., there are ¨150,000 copies of monomeric AQP1
in every human red blood cell and AQP1 represents ¨2.4% of
total membrane protein, while in the kidney cortex this figure is
¨1% [41]. Additionally, we have shown that polarized salivary
epithelial cells, after in vitro infection with AdhAQP1 at a
MOI=1 pfu/cell, respond well physiologically to imposed
osmotic gradients even as steep as 300 mosm (i.e., 640 mosm
apical; 340 mosm basal) [24]. This MOI, which leads to high
levels of AQP1 expression (¨30% that seen in 5 Ag crude rat
kidney membranes), as well as this osmotic gradient, are far in
excess of that which cells can reasonably be expected to be
exposed in vivo in patients in the proposed clinical study. Thus,
taken together these observations support the notion that the
risk: benefit ratio for hAQP1 cDNA transfer to patients in the
proposed clinical trial is quite low.
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